You are here

Article Text

Article menu
Download PDFPDF
Letter
Adalimumab use in pregnancy
  1. L Vesga,
  2. J P Terdiman,
  3. U Mahadevan
  1. Division of Gastroenterology, University of California, San Francisco, USA
  1. Correspondence to:
    Dr U Mahadevan MD
    Division of Gastroenterology, University of California, 2330 Post Street, #610, San Francisco, CA 94115, USA; umamah{at}itsa.ucsf.edu

https://doi.org/10.1136/gut.2005.065417

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Infliximab, a chimeric antibody to tumour necrosis factor alpha (TNF-α), has demonstrated efficacy for the induction and maintenance of remission in patients with Crohn’s disease.1,2 Antibodies to the chimeric component of infliximab can lead to infusion reactions and possible loss of response.3 A human recombinant monoclonal antibody to TNF-α, adalimumab, has recently demonstrated safety and efficacy for induction of remission in Crohn’s disease.4 It has also been effective in patients who have lost response to infliximab.5 Currently, this drug is FDA approved for the treatment of rheumatoid arthritis but it is being administered off label to patients with Crohn’s disease who …

    View Full Text